REFRACTORY LYMPHOMA
Clinical trials for REFRACTORY LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with relapsed cancers: experimental drug CBL0137 enters trial
Disease control Recruiting nowThis study tests a new drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the best dose, check side effects, and see if the drug can shrink tumors. The…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Vitamin c boost: could high doses help chemo fight tough blood cancers?
Disease control Recruiting nowThis study tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy can help kill cancer cells better in people with certain blood cancers that have returned or not responded to treatment. It includes adults with relapsed or refractory lymphoma, clonal cy…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Engineered immune cells take on hard-to-treat lymphoma in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New cocktail aims to beat back lymphoma when other treatments fail
Disease control Recruiting nowThis phase 2 trial is testing a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in 45 people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo shrinks tumors and how safe it …
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE2 • Sponsor: Reid Merryman, MD • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for kids with tough cancers: precision drugs tested
Disease control Recruiting nowThis trial tests whether giving children and teens with advanced solid tumors, brain tumors, or lymphomas drugs that match their tumor's genetic profile can help. About 90 participants will receive one of four drug combinations based on their tumor's molecular features. The goal …
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Australian & New Zealand Children's Haematology/Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail aims to tackle tough lymphoma
Disease control Recruiting nowThis study tests a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—for people with mantle cell lymphoma that has come back or hasn't been treated yet. The goal is to find the best dose and see how well it works at shrinking tumors. About 72 participants wil…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Austin I Kim • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR-T cell therapy called LMY-920 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. The therapy uses a protein called BAFF to help th…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Card game aims to ease tough End-of-Life talks for cancer patients
Symptom relief Recruiting nowThis study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…
Matched conditions: REFRACTORY LYMPHOMA
Phase: NA • Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC